Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
- Conditions
- Interventions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT06735248
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 2450
- Registration Number
- NCT06694389
- Locations
- 🇯🇵
Fukuoka Heartnet Hospital, Fukuoka-shi, Fukuoka, Japan
🇯🇵Medical Coporation of Yamazaki Neurotology, Rhinolaryngology Clinical, Sapporo-shi, Hokkaido, Japan
🇯🇵Motomachi Takatsuka Naika Clinic - Internal Medicine, Yokohama-shi, Kanagawa, Japan
A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT06655870
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06634797
- Locations
- 🇺🇸
Velocity Clinical Research, Phoenix, Phoenix, Arizona, United States
🇺🇸Velocity Clinical Research, Huntington Park, Huntington Park, California, United States
🇺🇸Velocity Clinical Research, San Diego, La Mesa, California, United States
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 56000
- Registration Number
- NCT06602024
- Locations
- 🇺🇸
ARS - Meridien Research, Maitland, Florida, United States
🇺🇸K2 medical research, Maitland, Florida, United States
🇺🇸Floridian Clinical Research, Miami Lakes, Florida, United States
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 25000
- Registration Number
- NCT06592794
- Locations
- 🇺🇸
Integrity Clinical Research, LLC (ICR SITES) - Doral, Doral, Florida, United States
🇺🇸Alliance for multispecialty Research - Florida, Doral, Florida, United States
🇺🇸AGA Clinical Trials, Hialeah, Florida, United States
A Study to Investigate the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in Adults to Prevent COVID-19
- Conditions
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06585241
- Locations
- 🇺🇸
CenExel iResearch, LLC, Decatur, Georgia, United States
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT06508320
- Locations
- 🇺🇸
Indago Research & Health Center, Inc., Hialeah, Florida, United States
🇺🇸DM Clinical Research - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Clinical Trials of Texas, LLC DBA Flourish Research, San Antonio, Texas, United States
Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
- Conditions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1192
- Registration Number
- NCT06369272
- Locations
- 🇺🇸
Carelon Research, Newton, Massachusetts, United States
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 215
- Registration Number
- NCT06354998
- Locations
- 🇦🇺
Paratus Canberra, Canberra, Australian Capital Territory, Australia
🇦🇺Holdsworth House, Darlinghurst, New South Wales, Australia
🇦🇺USC Morayfield, Morayfield, Queensland, Australia